Persistent decline of hospitalizations for acute stroke and acute coronary syndrome during the second wave of the COVID-19 pandemic in Greece: collateral damage unaffected.
COVID-19
Greece
acute coronary syndromes
admissions
intracerebral haemorrhage
ischaemic stroke
stroke
Journal
Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
04
2021
accepted:
09
06
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
22
7
2021
Statut:
epublish
Résumé
An alarming cerebro/cardiovascular collateral damage, reflected by a decline in admissions for acute stroke (AS) and acute coronary syndrome (ACS), was observed during the initial phase of the COVID-19 pandemic, thereby leading to a re-design of public campaigns. However, there are limited data regarding the AS and ACS hospitalization rates during the second wave of the pandemic, which was followed by re-imposition of lockdowns. We calculated the rate of AS and ACS hospitalizations from three representative tertiary care hospitals in Greece during a 2-month period (November-December 2020) of the second wave of the COVID-19 pandemic compared with the corresponding control period in 2019 from three representative tertiary care hospitals in Greece. This was a follow-up study with identical design to our previous report evaluating AS and ACS hospitalizations during the first wave of the pandemic (March-April 2020). Compared with 2019, there was a 34% relative reduction of AS hospitalizations [incidence rate ratio (IRR): 0.66, 95% confidence interval (CI): 0.48-0.92, AS and ACS hospitalizations were persistently reduced during the second wave of the COVID-19 pandemic compared with 2019 in Greece. This decline was similar to the observations during the first wave despite the large differences in the epidemiological COVID-19 burden. Lockdowns, a common characteristic in both waves, appear to have a detrimental indirect impact on cerebro/cardiovascular diseases in the general population.
Sections du résumé
BACKGROUND
BACKGROUND
An alarming cerebro/cardiovascular collateral damage, reflected by a decline in admissions for acute stroke (AS) and acute coronary syndrome (ACS), was observed during the initial phase of the COVID-19 pandemic, thereby leading to a re-design of public campaigns. However, there are limited data regarding the AS and ACS hospitalization rates during the second wave of the pandemic, which was followed by re-imposition of lockdowns.
METHODS
METHODS
We calculated the rate of AS and ACS hospitalizations from three representative tertiary care hospitals in Greece during a 2-month period (November-December 2020) of the second wave of the COVID-19 pandemic compared with the corresponding control period in 2019 from three representative tertiary care hospitals in Greece. This was a follow-up study with identical design to our previous report evaluating AS and ACS hospitalizations during the first wave of the pandemic (March-April 2020).
RESULTS
RESULTS
Compared with 2019, there was a 34% relative reduction of AS hospitalizations [incidence rate ratio (IRR): 0.66, 95% confidence interval (CI): 0.48-0.92,
CONCLUSION
CONCLUSIONS
AS and ACS hospitalizations were persistently reduced during the second wave of the COVID-19 pandemic compared with 2019 in Greece. This decline was similar to the observations during the first wave despite the large differences in the epidemiological COVID-19 burden. Lockdowns, a common characteristic in both waves, appear to have a detrimental indirect impact on cerebro/cardiovascular diseases in the general population.
Identifiants
pubmed: 34285718
doi: 10.1177/17562864211029540
pii: 10.1177_17562864211029540
pmc: PMC8267023
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17562864211029540Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: Georgios Tsivgoulis is Associate Editor at Therapeutic Advances in Neurological Disorders, therefore, the peer review process was managed by alternative members of the Board and the submitting Editor was not involved in the decision-making process.
Références
J Am Coll Cardiol. 2021 Mar 2;77(8):1141-1143
pubmed: 33483137
JAMA Netw Open. 2020 Jul 1;3(7):e2014323
pubmed: 32639569
Ther Adv Neurol Disord. 2020 Dec 8;13:1756286420978004
pubmed: 33343709
Ther Adv Neurol Disord. 2020 Jun 9;13:1756286420932036
pubmed: 32565914
Stroke. 2020 Jul;51(7):2224-2227
pubmed: 32516064
Stroke. 2020 Sep;51(9):2664-2673
pubmed: 32755347
Stroke. 2020 Aug;51(8):2307-2314
pubmed: 32466738
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104953
pubmed: 32689621
Resusc Plus. 2021 Mar;5:100066
pubmed: 33521706
Am Heart J. 2021 Feb;232:146-153
pubmed: 33160947
Ann Neurol. 2021 Feb;89(2):380-388
pubmed: 33219563
Eur J Neurol. 2020 Dec 8;:
pubmed: 33290619
Stroke. 2021 Jan;52(2):716-721
pubmed: 33356382
Stroke. 2020 Aug;51(8):2315-2321
pubmed: 32530738
N Engl J Med. 2020 Jul 2;383(1):88-89
pubmed: 32343497
JAMA. 2000 Jul 5;284(1):60-7
pubmed: 10872014
Front Cardiovasc Med. 2021 Feb 11;8:604374
pubmed: 33644128
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
Eur Heart J. 2020 Jun 1;41(32):3045-3054
pubmed: 32562486
Heart. 1996 Nov;76(5):430-4
pubmed: 8944590
Clin Cardiol. 2020 Oct;43(10):1142-1149
pubmed: 32691901
Public Health. 2021 Feb;191:17-19
pubmed: 33472127